Year: 2025
Type: article
Abstract: BACKGROUND: Clinical trials are crucial in advancing novel therapies for thyroid cancer. Given the increased cost of modern healthcare, cost considerations in clinical trials are important yet remain under-reported. METHODS: A search of ClinicalTrials.gov identified thyroid cancer studies including cost in the trial description or as an outcome. Data collected included trial information, cost outcomes, and cost-effectiveness analyses. RESULTS: Among 46 thyroid cancer-focused clinical trials, only 28 (60.8 %) mentioned cost in any capacity, of which 21 (75 %) included cost outcomes and 7 (25 %) included cost-effectiveness analyses. Overall, cost was a primary outcome in 1 (2.2 %) trial, secondary outcome in 20 (43.5 %) trials, and exploratory outcome in 7 (15.2 %) trials. CONCLUSION: The inclusion of cost analysis in thyroid cancer clinical trials is limited. Given rising cost pressures in modern healthcare systems, the low prevalence of cost endpoints and cost-effectiveness analyses underscores the need for increased awareness and investment in this domain.
Source: The American Journal of Surgery
Authors: James L. Rogers, Sebastian Henostroza, Adam Fahey, Carmen C. Solórzano
Institutions: Vanderbilt University, Vanderbilt University Medical Center
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: hybrid
Estimated APC paid: $3,830
Funder: National Institutes of Health
OpenAlex ID: W4417304981